Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes and Microvesicles

Davina Gale's Biography

Davina Gale, Head of Molecular Diagnostics, Co-Founder, Inivata

Davina Gale is co-founder and Head of Molecular Diagnostics at Inivata, a clinical cancer genomics company developing clinical applications of circulating tumour DNA (ctDNA) to improve testing and treatment for oncologists and their patients. Prior to this, Davina worked for 20 years in the pharmaceutical industry, gaining expertise in the identification and validation of novel genomic disease biomarkers, including incorporating their use in Phase I/IIa clinical trials. She subsequently joined Nitzan Rosenfeld’s group as Lab Manager of the Molecular and Computational Diagnostics group at the Cancer Research UK Cambridge Institute, University of Cambridge. She is part of the team that pioneered novel next generation sequencing approaches for analysis of ctDNA, including development of the TAm-Seq™ technology, which has been licensed to Inivata for the analysis of ctDNA as a non-invasive ‘liquid’ biopsy for personalised cancer therapy.

Davina Gale Image

Noninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor DNA

Monday, 23 March 2015 at 12:00

Add to Calendar ▼2015-03-23 12:00:002015-03-23 13:00:00Europe/LondonNoninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor

Novel biomarkers are required to accurately assess tumour burden and response in cancer.  Circulating tumour DNA (ctDNA), containing tumour-specific DNA alterations, is present in patient plasma as a fraction of the total cell-free DNA.  The study of ctDNA levels and mutational profile could potentially inform clinical decision making, be used to monitor tumour dynamics, assess response to treatment and identify mutations associated with acquired drug resistance.  Inivata is a clinical cancer genomics company focused on harnessing the emerging potential of circulating DNA analysis to improve cancer testing and treatment.  Novel applications of ctDNA are enabled by Inivata’s technology platform which includes its proprietary enhanced TAm-Seq™ technology, to allow the detection and analysis of genomic material from a cancer patient’s cell-free DNA collected through routinely accessible blood samples. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonExosomes and